For adults with T2D receiving SGLT2is, risk factors for ketoacidosis include high HbA1c, previous ketoacidosis, and recent hypoglycemia.

COVID-19 infection is associated with a lower risk for developing type 1 diabetes (T1D) in individuals younger than 30 years.

The FDA has granted Priority Review to Alexion's BLA for efzimfotase alfa, a biweekly enzyme replacement therapy for hypophosphatasia.

The FDA has approved Kerendia (finerenone) to reduce UACR, which is expected to slow CKD progression in adults with type 1 diabetes.

A proposed machine learning framework for metabolic dysfunction-associated steatotic liver disease may improve personalized risk prediction.

Cultural stigma and sensationalized media narratives regarding GLP-1 RAs contribute to patient drug avoidance and treatment ...

The SMFM released a special statement to offer a structured, multidisciplinary approach to managing sickle cell disease and vaso-occlusive crises during pregnancy.

All participating U.S. comprehensive cancer centers are experiencing a shortage of at least one anticancer agent, with more than 20 percent of centers currently ...

High-risk proteomic signatures for cardiometabolic disease emerge during childhood but remain modifiable through adult GLP-1 therapy.

Strict glycemic control failed to lower microvascular and macrovascular event rates, but increased hypoglycemia, in older ...

Exocrine pancreatic insufficiency is prevalent among adults with T1D and is linked to higher hemoglobin A1c and mean glucose levels.

The FDA has accepted the Biologics License Application for SkinTE, granting it Priority Review for the treatment of Wagner grade 1 diabetic foot ulcers.